摘要:
The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. Formule (I).
摘要:
Polycyclic aryl and polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl catalytic activity are also disclosed.
摘要:
The invention relates to compounds that are 4-substituted azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.
摘要:
The invention relates to compounds that are substituted aminomethyl azaadamantane derivatives of formula ( I ), compositions comprising such compounds, and the use of such compounds and compositions for treating or preventing conditions, disorders or deficits modulated by an α7 nicotinic acetylcholine receptor, an α4β2 nicotinic aetylcholine receptor or both α.7 and α4β2 nicotinic acetylcholine receptor wherein the condition, disorder or deficit is selected from the group consisting of a memory disorder, cognitive disorder, neurodegeneration, and neυrodevelopmental disorder.
摘要:
Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
摘要:
The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要:
The invention relates to novel heterocyclic compounds having general formula (I) and the salts thereof with a base or an acid. The invention also relates to a method of preparing said compounds and to the use of same as medicaments, such as anti-bacterial medicaments and β-lactamase inhibitors.
摘要:
L'invention concerne de nouveaux composés hétérocycliques intermédiaires dans la synthèse des composés de formule générale (I) et de leurs sels avec une base ou un acide :
Les composés de formule (I) sont utiles comme médicaments, notamment comme anti-bactériens.